Role and prognostic significance of the Ki‐67 index in non‐Hodgkin's lymphoma

Expression of Ki‐67, a nuclear antigen protein present in all cycling cells, is used to determine the growth fraction of tumors. The aim of this study was to evaluate the role and prognostic significance of the Ki‐67 proliferation index (PI) in non‐Hodgkin's lymphoma. Ki‐67 was assayed immunohistochemically in tissue samples of 319 patients with newly‐diagnosed non‐Hodgkin's lymphoma. In 268 patients, the Ki‐67 PI was correlated with clinical course and outcome. The mean Ki‐67 PI ranged from 26.6% in indolent lymphomas to 97.6% in very aggressive lymphomas (P < 0.001). The index was <45% in 82.8% of indolent lymphomas and >45% in 85% of aggressive lymphomas (AUC = 0.877, P < 0.001). In patients with diffuse large B‐cell lymphoma (n = 141), a Ki‐67 PI of 70% was found to significantly discriminate patients with good or bad prognosis (AUC = 0.65, P = 0.004). Three‐year survival was 75% ± 5.6% in patients with a low Ki‐67 index compared with 55.9% ± 6% in patients with a high index (P = 0.015). In patients with a low IPI (≤2), 3‐year survival was 94% ± 4% in those with a Ki‐67 index ≤70% and 64% ± 8.1% in those with a higher index (P = 0.002); in patients with bulky disease (>10 cm), the corresponding 3‐year survival by Ki‐67 index was 100% and 25% ± 12% (P = 0.012). Our results suggest that the mean Ki‐67 PI differs by type of lymphoma. A cut‐off value of 45% can help differentiate indolent from aggressive disease. In diffuse large B‐cell lymphoma, a cut‐off value of 70% can distinguish patients with a good and bad prognosis when combined with other prognostic factors of low IPI score and bulky disease. Am. J. Hematol. 2009. © 2009 Wiley‐Liss, Inc.

[1]  L. Gordon,et al.  Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas. , 1996, Blood.

[2]  J. Gerdes,et al.  The Ki-67 protein: fascinating forms and an unknown function. , 2000, Experimental cell research.

[3]  T. Lister,et al.  The prognostic value of Ki67 immunostaining in non‐Hodgkin's lymphoma , 1988, The Journal of pathology.

[4]  Johannes Gerdes,et al.  The Ki‐67 protein: From the known and the unknown , 2000, Journal of cellular physiology.

[5]  J. Krueger,et al.  Classification of Non-Hodgkin's Lymphoma: A Proposal. , 1997, The oncologist.

[6]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  A. Rosenwald,et al.  Burkitt lymphoma versus diffuse large B-cell lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  T. Grogan,et al.  Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67 , 1988 .

[9]  W. Chan,et al.  Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. , 1995, Blood.

[10]  D Schmidt,et al.  Prognostic significance of the proliferative activity in neuroblastoma. , 1997, The American journal of pathology.

[11]  Andrew Lister,et al.  Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[13]  G. Palestro,et al.  MIB-1, Ki67, and PCNA scores and DNA flow cytometry in intermediate grade malignant lymphomas. , 1994, Journal of clinical pathology.

[14]  C. Dunphy,et al.  Grading of follicular lymphoma: comparison of routine histology with immunohistochemistry. , 2007, Archives of pathology & laboratory medicine.

[15]  K. Gatter,et al.  Ki67 protein: the immaculate deception? , 2002, Histopathology.

[16]  F. Schmitt,et al.  Proliferating Cell Nuclear Antigen (Pcna) In Non‐Hodgkin'S Lymphomas: Correlation with Working Formulation and Kiel classification in formalin‐fixed paraffin‐embedded material , 1996, Pathology.

[17]  G. Pruneri,et al.  Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki‐67 labeling index , 2004, International journal of cancer.

[18]  S. Pileri,et al.  PROGNOSTIC RELEVANCE OF TUMOUR-CELL GROWTH FRACTION IN MALIGNANT NON-HODGKIN'S LYMPHOMAS , 1987, The Lancet.

[19]  J. Overgaard,et al.  Immunohistochemical BCL-2 and Ki-67 expression predict survival in prostate cancer patients followed expectantly , 1999, Prostate Cancer and Prostatic Diseases.

[20]  A. Cnaan,et al.  Proliferation markers in breast carcinoma. , 1996, American journal of clinical pathology.

[21]  Ellen,et al.  Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. , 1994, Blood.

[22]  S. Kvaløy,et al.  Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma—a Nordic Lymphoma Group study , 2004, Annals of Hematology.

[23]  N. Harris,et al.  Low Histologic Grade Follicular Lymphoma With High Proliferation Index: Morphologic and Clinical Features , 2005, The American journal of surgical pathology.

[24]  Nicola Pimpinelli,et al.  WHO-EORTC classification for cutaneous lymphomas. , 2005, Blood.

[25]  C. Cordon-Cardo,et al.  Ki‐67 detected by MIB‐1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma , 1998, Cancer.